JP2024516595A5 - - Google Patents
Info
- Publication number
- JP2024516595A5 JP2024516595A5 JP2023563978A JP2023563978A JP2024516595A5 JP 2024516595 A5 JP2024516595 A5 JP 2024516595A5 JP 2023563978 A JP2023563978 A JP 2023563978A JP 2023563978 A JP2023563978 A JP 2023563978A JP 2024516595 A5 JP2024516595 A5 JP 2024516595A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- fragment
- tslp
- amino acid
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163178915P | 2021-04-23 | 2021-04-23 | |
| US63/178,915 | 2021-04-23 | ||
| PCT/US2022/025999 WO2022226342A2 (en) | 2021-04-23 | 2022-04-22 | Modified anti-tslp antibodies |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024516595A JP2024516595A (ja) | 2024-04-16 |
| JP2024516595A5 true JP2024516595A5 (enExample) | 2025-05-01 |
Family
ID=81597885
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023563978A Pending JP2024516595A (ja) | 2021-04-23 | 2022-04-22 | 修飾された抗ｔｓｌｐ抗体 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20240182558A1 (enExample) |
| EP (1) | EP4326762A2 (enExample) |
| JP (1) | JP2024516595A (enExample) |
| KR (1) | KR20230175245A (enExample) |
| CN (1) | CN117177992A (enExample) |
| AR (1) | AR125404A1 (enExample) |
| AU (1) | AU2022262006A1 (enExample) |
| BR (1) | BR112023022041A2 (enExample) |
| CA (1) | CA3216700A1 (enExample) |
| CL (1) | CL2023003124A1 (enExample) |
| IL (1) | IL307439A (enExample) |
| MX (1) | MX2023012325A (enExample) |
| TW (1) | TW202304980A (enExample) |
| WO (1) | WO2022226342A2 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12110324B2 (en) | 2022-07-22 | 2024-10-08 | Flagship Pioneering Innovations Vi, Llc | Antigen binding molecules targeting thymic stromal lymphopoietin (TSLP) |
| WO2024118542A1 (en) * | 2022-11-28 | 2024-06-06 | Takeda Vaccines, Inc. | A method for the quantitative determination of human serum albumin monomer in virus-containing pharmaceutical compositions |
| EP4647084A1 (en) * | 2023-01-06 | 2025-11-12 | Jiangsu Hengrui Pharmaceuticals Co., Ltd. | Method for treating asthma by using tslp antibody |
| TW202448501A (zh) | 2023-02-02 | 2024-12-16 | 美商麥迪紐有限責任公司 | 用抗ｔｓｌｐ抗體治療慢性鼻竇炎 |
| IL324470A (en) | 2023-05-18 | 2026-01-01 | Medimmune Llc | Treatment of corticosteroid-dependent asthma using anti-TSLP antibody |
| WO2025147632A1 (en) | 2024-01-05 | 2025-07-10 | Medimmune, Llc | Treatment of chronic obstructive pulmonary disease with anti-tslp antibody |
| WO2025221247A1 (en) | 2024-04-17 | 2025-10-23 | Amgen Inc. | Treatment of eosinophilic esophagitis with anti-tslp antibody |
| WO2025265071A1 (en) * | 2024-06-21 | 2025-12-26 | Paragon Therapeutics, Inc. | Antibodies that bind tslp and methods of use |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| ATE158021T1 (de) | 1990-08-29 | 1997-09-15 | Genpharm Int | Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper |
| US8716451B2 (en) * | 2005-01-12 | 2014-05-06 | Kyowa Hakko Kirin Co., Ltd | Stabilized human IgG2 and IgG3 antibodies |
| US7982016B2 (en) * | 2007-09-10 | 2011-07-19 | Amgen Inc. | Antigen binding proteins capable of binding thymic stromal lymphopoietin |
| US8359965B2 (en) | 2007-09-17 | 2013-01-29 | Oxford J Craig | Apparatus and method for broad spectrum radiation attenuation |
| ES2595638T3 (es) * | 2007-09-26 | 2017-01-02 | Chugai Seiyaku Kabushiki Kaisha | Método para modificar el punto isoeléctrico de un anticuerpo mediante la sustitución de aminoácidos en una CDR |
| WO2012007495A1 (en) | 2010-07-15 | 2012-01-19 | F. Hoffmann-La Roche Ag | Antibodies specifically binding to human tslpr and methods of use |
| AT510032B1 (de) | 2010-11-30 | 2012-01-15 | Steiner Erwin Ing | Montageeinrichtung für fassadenelemente |
| US9100245B1 (en) | 2012-02-08 | 2015-08-04 | Amazon Technologies, Inc. | Identifying protected media files |
| WO2014031718A1 (en) * | 2012-08-23 | 2014-02-27 | Merck Sharp & Dohme Corp. | Stable formulations of antibodies to tslp |
| US9306926B2 (en) | 2013-03-15 | 2016-04-05 | Brian A. Truong | User authentication using unique hidden identifiers |
| KR20170123315A (ko) * | 2015-03-11 | 2017-11-07 | 글락소스미스클라인 인털렉츄얼 프로퍼티 디벨로프먼트 리미티드 | Tslp 결합 단백질 |
| KR102666879B1 (ko) | 2017-04-12 | 2024-05-23 | 암젠 인크 | 항-tslp 항체를 이용한 천식의 치료 |
| JP7200134B2 (ja) | 2017-06-08 | 2023-01-06 | アムジエン・インコーポレーテツド | トルク駆動式薬物送達デバイス |
| ES2978396T3 (es) * | 2017-08-01 | 2024-09-11 | Amgen Inc | Sistemas y métodos para la preparación en tiempo real de una muestra de polipéptidos para el análisis por espectrometría de masas |
| MA50557A (fr) | 2017-11-10 | 2020-09-16 | Amgen Inc | Pistons pour dispositifs d'administration de médicament |
| EP4321870B1 (en) | 2018-03-13 | 2025-07-30 | Amgen Inc. | Methods for the preparation of trypsin-resistant polypeptides for mass spectrometric analysis |
| TW202541859A (zh) | 2018-10-15 | 2025-11-01 | 美商安進公司 | 具有阻尼機構之藥物遞送裝置及自動注射器 |
| WO2020081480A1 (en) | 2018-10-15 | 2020-04-23 | Amgen Inc. | Platform assembly process for drug delivery device |
| AU2020288652A1 (en) | 2019-06-05 | 2021-11-18 | Amgen Inc. | Methods of identifying attributes of therapeutic proteins |
| EP4025602A4 (en) * | 2019-09-04 | 2023-12-13 | Biosion, Inc. | TSLP BINDING ANTIBODIES AND USES THEREOF |
-
2022
- 2022-04-22 KR KR1020237039566A patent/KR20230175245A/ko active Pending
- 2022-04-22 CN CN202280030029.7A patent/CN117177992A/zh active Pending
- 2022-04-22 BR BR112023022041A patent/BR112023022041A2/pt unknown
- 2022-04-22 EP EP22722641.2A patent/EP4326762A2/en active Pending
- 2022-04-22 WO PCT/US2022/025999 patent/WO2022226342A2/en not_active Ceased
- 2022-04-22 US US18/287,597 patent/US20240182558A1/en active Pending
- 2022-04-22 MX MX2023012325A patent/MX2023012325A/es unknown
- 2022-04-22 JP JP2023563978A patent/JP2024516595A/ja active Pending
- 2022-04-22 TW TW111115432A patent/TW202304980A/zh unknown
- 2022-04-22 AU AU2022262006A patent/AU2022262006A1/en active Pending
- 2022-04-22 IL IL307439A patent/IL307439A/en unknown
- 2022-04-22 CA CA3216700A patent/CA3216700A1/en active Pending
- 2022-04-22 AR ARP220101043A patent/AR125404A1/es unknown
-
2023
- 2023-10-19 CL CL2023003124A patent/CL2023003124A1/es unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024516595A5 (enExample) | ||
| JP2024150751A5 (enExample) | ||
| JP2025016349A5 (enExample) | ||
| AU2018335823B2 (en) | Novel stable antibody variable domain framework combinations | |
| JP2010538608A5 (enExample) | ||
| JP2018516853A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| RU2018137811A (ru) | Антитела против il-33, композиции, способы и их применение | |
| JP2018522541A5 (enExample) | ||
| JP2010246565A5 (enExample) | ||
| JP2018519364A5 (enExample) | ||
| JP2010534478A5 (enExample) | ||
| JP2025500971A5 (enExample) | ||
| JP2021530244A5 (enExample) | ||
| JP2020514277A5 (enExample) | ||
| JP2018522888A5 (enExample) | ||
| JP2022529154A5 (enExample) | ||
| JP2012530487A5 (enExample) | ||
| JP2022549172A5 (enExample) | ||
| JP2023508674A5 (enExample) | ||
| JP2023545183A5 (enExample) | ||
| JP2022540620A5 (enExample) | ||
| JP2023545182A5 (enExample) | ||
| JP2020513759A5 (enExample) | ||
| RU2019121106A (ru) | Иммунотерапия с применением антител, связывающих белок 1 программируемой смерти клеток (pd-1) |